Healthcare Belgian Community

Agfa-Gevaert: A New Lease of Life Through Digitalisation and Materials Innovation A Careful Industrial Repositioning, Driven by Discipline, Digitalisation, and Speciality Materials Agfa-Gevaert (Euronext: AGFB) has undergone a transformation from an iconic photographic company into a focused digital imaging and specialty materials company. Following the sale of its Offset Solutions division to Aurelius Group in 2023, Agfa significantly reduced its exposure to the cyclical print sector and freed up capital for growth in higher-margin segments, such as digital radiology, industrial inkjet, and advanced chemical materials.Read more

Key Takeaways Genio's unique features and focused U.S. rollout strategy could enable rapid market share gains, higher utilization, and sustained margin expansion. Nyxoah is positioned to benefit from global OSA diagnosis trends and expanding patient eligibility, driving long-term revenue growth above market expectations.Read more

Key Takeaways Expansion into new regions and focus on personalized pharmaceuticals positions Fagron for future global growth as demand rises from aging populations and chronic conditions. Investment in automation, facility expansion, and quality strengthens operational efficiency and market leadership, paving the way for margin and earnings growth.Read more

Key Takeaways Sustained demand for advanced proton therapy and expansion into new markets are driving long-term revenue growth and improved earnings visibility. Continued R&D investments and growth in service contracts are enhancing margins, competitive positioning, and recurring high-margin revenue streams.Read more

Key Takeaways Regulatory, reimbursement, and administrative hurdles in the U.S. could restrict revenue growth, delay account expansion, and compress margins despite strong market demand. Innovation pressures, rising R&D costs, and increased competition threaten long-term profitability, market share, and Genio's premium product positioning.Read more

Key Takeaways Recent regulatory approval and a distinctive product profile position Nyxoah for rapid growth and wider market penetration in the evolving sleep apnea landscape. Expanding clinical adoption, favorable reimbursement trends, and future indications support accelerating revenue, margin expansion, and scalable commercial success.Read more